- Conditions
- Glaucoma
- Interventions
- ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- HIV-1 gag DNA, IL-15 DNA adjuvant, IL-12 DNA adjuvant
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2008
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
- Conditions
- Limited-Stage Small Cell Lung Cancer
- Interventions
- HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
- Drug · Radiation
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 31
- States / cities
- Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more
- Conditions
- Obesity, Adolescent
- Interventions
- Qsymia and lifestyle management therapy, Placebo and lifestyle management therapy
- Drug · Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 16 Years to 22 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- HIV Infections
- Interventions
- pGA2/JS7 DNA vaccine, Placebo, MVA/HIV62 vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Interventions
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 280
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- ADXS11-001 (Lm-LLO-E7), Placebo Control
- Biological · Drug
- Lead sponsor
- Advaxis, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more
- Conditions
- Bacterial Infections
- Interventions
- Ciprofloxacin single dose, Ciprofloxacin triple dose
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 497 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
- Conditions
- First Trimester Abortion
- Interventions
- Azithromycin, Doxycycline, Metronidazole, Placebo
- Drug
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Silver Spring, Maryland
- Conditions
- Glycogen Storage Disease Type IA
- Interventions
- DTX401, Placebo, Oral prednisolone, Placebo for oral prednisolone
- Genetic · Other · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 9
- States / cities
- Orange, California • Aurora, Colorado • Farmington, Connecticut + 6 more
- Conditions
- Migraine
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- Ad26.ZEBOV, MVA-BN-Filo, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Anthrax
- Interventions
- AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
- Biological
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
- Conditions
- Migraine
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 179
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more